{"classes":[{"categories":[{"measurements":[{"comment":"NA = Median DOR and DOR upper limit were not reached by the time of last disease assessment.","groupId":"OG000","lowerLimit":"6.2","upperLimit":"NA","value":"NA"},{"comment":"NA = Median DOR and DOR upper limit were not reached by the time of last disease assessment.","groupId":"OG001","lowerLimit":"4.4","upperLimit":"NA","value":"NA"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"20"},{"groupId":"OG001","value":"22"}],"units":"Participants"}],"description":"For participants who demonstrated a CR or PR, duration of response was defined as the time from first documented evidence of CR or PR until disease progression or death due to any cause, whichever occurred first. Complete Response: disappearance of all target lesions. Partial Response: at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. Responses were based upon blinded central imaging vendor per RECIST 1.1. Duration of Response was based on Independent radiologist review (IRC) using RECIST 1.1 and was summarized by Kaplan-Meier (KM) methods for censored data. Nonresponders were excluded from the analysis of DOR.","dispersionType":"Full Range","groups":[{"description":"Participants were previously treated with standard therapies, which must include fluoropyrimidine, oxaliplatin, and irinotecan. Cohort A participants received pembrolizumab 200 mg intravenously (IV) on Day 1 of every 3-week cycle (Q3W) for up to approximately 35 cycles (up to approximately 2 years).","id":"OG000","title":"Cohort A - Pembrolizumab 200 mg"},{"description":"Participants were previously treated with at least one line of systemic standard of care therapy: fluoropyrimidine + oxaliplatin or fluoropyrimidine + irinotecan +/ - anti vascular endothelial growth factor (VEGF)/ epidermal growth factor regulator (EGFR) monoclonal antibody. Cohort B participants received pembrolizumab 200 mg IV on Day 1 Q3W for up to approximately 35 cycles (up to approximately 2 years).","id":"OG001","title":"Cohort B - Pembrolizumab 200 mg"}],"paramType":"MEDIAN","populationDescription":"The analysis population consisted of all participants who received at least one dose of study treatment and demonstrated a CR or PR.","reportingStatus":"POSTED","timeFrame":"Up to approximately 66 months","title":"Duration of Response (DOR) Per RECIST 1.1 as Assessed by the Central Imaging Vendor","type":"SECONDARY","unitOfMeasure":"Months"}